Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek regulatory approvals by the end of the year.

Eli Lilly on Thursday reported promising results for a daily pill that could serve as an alternative to injectable weight-loss and diabetes drugs. Why it matters: One thing hampering the GLP-1 drug boom is the fact that they're shots — not oral medications — which keeps some prospective patients from taking them.